publication . Article . 2005

Clinical status of agents being developed for leishmaniasis

Jonathan Berman;
Open Access
  • Published: 28 Oct 2005
Leishmaniasis, which exists in both visceral and cutaneous forms, is currently treated with intramuscular antimony or intravenous amphotericin B. The primary unmet need is for oral therapy. Of the several drugs in clinical development, miltefosine is unique in being an oral agent with efficacy against both forms of the disease. Sitamaquine is an oral agent with substantial but not sufficient efficacy against visceral disease. Oral fluconazole has been shown to be more effective than placebo in one instance: for Leishmania major cutaneous disease from Saudi Arabia. Paromomycin is in widespread trial. Topical paromomycin formulations are being tested for cutaneous...
Persistent Identifiers
Medical Subject Headings: parasitic diseasescarbohydrates (lipids)
free text keywords: Pharmacology (medical), Pharmacology, General Medicine, Placebo, Miltefosine, medicine.drug, medicine, Ketoconazole, Fluconazole, Paromomycin, business.industry, business, Leishmania major, biology.organism_classification, biology, Disease, Dermatology, medicine.medical_specialty, Leishmaniasis, medicine.disease
Related Organizations
Any information missing or wrong?Report an Issue